ASSESSMENT OF SURGICAL RISK IN PATIENTS WITH CHRONIC LIVER DISEASE USING VOCAL PENN SCORE
Launched by ASIAN INSTITUTE OF GASTROENTEROLOGY, INDIA · Jan 19, 2024
Trial Information
Current as of July 15, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a specific scoring system, called the VOCAL PENN score, can predict the risk of dying after surgery in patients with chronic liver disease, specifically those with cirrhosis. The researchers want to compare this new score with an existing system called MELD to see which one is more accurate in predicting the chances of survival 30 and 90 days after surgery.
To be eligible for this trial, participants need to be adults aged 65 years and older who have been diagnosed with cirrhosis and are planning to undergo certain types of abdominal surgeries. Patients who have had a liver transplant, those who are having multiple surgeries at once, or those who cannot provide enough medical information will not be included. If you join the study, you’ll have your risk assessed using the VOCAL PENN score before your surgery, and the researchers will follow up with you afterward to see how you are doing. This trial is currently recruiting participants, and it aims to improve the way we understand surgical risks in people with chronic liver disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with established cirrhosis Patients who had not received liver transplantation and who underwent surgery of interest were included These surgery categories will be the same as those used in the original VOCAL-Penn derivation study and will include the open abdominal, laparoscopic abdominal, and abdominal wall.
- Exclusion Criteria:
- • Patients with insufficient pre-operative data to compute the VOCAL-Penn score, Mayo risk score, or MELD-Na score will be excluded.
- • Patients undergoing liver surgeries Patients who received multiple surgeries Those who didn't give consent
About Asian Institute Of Gastroenterology, India
The Asian Institute of Gastroenterology (AIG) in India is a premier healthcare institution specializing in advanced gastroenterology and hepatology. Renowned for its commitment to clinical excellence and innovative research, AIG conducts a range of clinical trials aimed at enhancing the understanding and treatment of gastrointestinal and liver disorders. With a multidisciplinary team of experienced clinicians and researchers, the institute leverages state-of-the-art technology and patient-centered approaches to contribute significantly to the advancement of medical knowledge and improved patient outcomes in the field of gastroenterology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hyderabad, Telangana, India
Patients applied
Trial Officials
PRACHITI Gokhe
Principal Investigator
AIG HOSPITALS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported